FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...
If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
However, in people with mild cognitive impairment, the presence of depressive symptoms was tied to a lower likelihood of amyloid pathology (OR 0.73, 95% CI 0.61-0.89, P =0.001), Oomens and colleagues ...
Health and Me on MSN4h
What Causes Bipolar Disorder? These 36 Genes Hold The AnswerBipolar disorder affects 40-50 million people globally, with genetic heritability between 60-80%, and can be triggered by both positive and negative life events, including promotions or new ...
Biochemical analyses provide an answer to the question of how the gut bacterium Morganella morganii might contribute to some ...
Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback